Insider Selling: Repligen Co. (NASDAQ:RGEN) CEO Sells 12,094 Shares of Stock

Share on StockTwits

Repligen Co. (NASDAQ:RGEN) CEO Anthony Hunt sold 12,094 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $82.40, for a total value of $996,545.60. Following the completion of the transaction, the chief executive officer now owns 210,976 shares in the company, valued at $17,384,422.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

RGEN stock traded down $0.69 during mid-day trading on Wednesday, hitting $79.88. The company had a trading volume of 1,073,938 shares, compared to its average volume of 461,140. The company has a market capitalization of $4.18 billion, a price-to-earnings ratio of 109.42, a P/E/G ratio of 4.82 and a beta of 1.16. Repligen Co. has a 12-month low of $48.26 and a 12-month high of $99.25. The company has a quick ratio of 1.88, a current ratio of 2.25 and a debt-to-equity ratio of 0.02. The company has a 50-day moving average price of $91.47 and a 200 day moving average price of $74.32.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported $0.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.25 by $0.06. Repligen had a return on equity of 6.92% and a net margin of 11.42%. The firm had revenue of $70.70 million during the quarter, compared to analyst estimates of $65.47 million. During the same quarter last year, the business posted $0.14 earnings per share. The business’s quarterly revenue was up 48.1% compared to the same quarter last year. As a group, analysts expect that Repligen Co. will post 0.97 EPS for the current year.

Several large investors have recently bought and sold shares of the stock. Atria Investments LLC purchased a new position in Repligen during the 2nd quarter valued at approximately $853,000. Mackenzie Financial Corp raised its stake in Repligen by 1,032.7% during the second quarter. Mackenzie Financial Corp now owns 84,160 shares of the biotechnology company’s stock valued at $7,234,000 after purchasing an additional 76,730 shares in the last quarter. BlackRock Inc. raised its stake in Repligen by 12.4% during the second quarter. BlackRock Inc. now owns 6,350,552 shares of the biotechnology company’s stock valued at $545,830,000 after purchasing an additional 699,886 shares in the last quarter. International Biotechnology Trust PLC bought a new position in Repligen during the second quarter valued at $2,061,000. Finally, Royal Bank of Canada lifted its position in Repligen by 26.6% during the second quarter. Royal Bank of Canada now owns 85,663 shares of the biotechnology company’s stock valued at $7,363,000 after purchasing an additional 17,985 shares during the last quarter. Institutional investors own 88.66% of the company’s stock.

Several analysts recently issued reports on RGEN shares. Craig Hallum increased their target price on Repligen from $80.00 to $108.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Stephens reissued an “overweight” rating and set a $110.00 target price on shares of Repligen in a research note on Thursday, August 22nd. ValuEngine cut Repligen from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 1st. First Analysis upped their price target on Repligen from $95.00 to $107.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $110.00 price objective on shares of Repligen in a report on Monday, August 12th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $101.17.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Article: What are the Benefits of Index Funds?

Insider Buying and Selling by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.